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Abstract Lymphoma-associated hemophagocytic syndrome
(LAHS), which is the major subtype of adult-onset secondary
hemophagocytic lymphohistiocytosis (HLH), has a poor out-
come. Although the early diagnosis and treatment of LAHS
contributes to a better outcome, the lack of mass formation and
the absence of distinct lymph node enlargement often delay the
diagnosis of underlying lymphoma. A recent study, which sta-
tistically analyzed HLH cases in the literature, showed that the
serum soluble interleukin-2 receptor (sIL-2R)/ferritin ratio could
be used as amarker to diagnosis of LAHS. To verify this finding,
we retrospectively analyzed the laboratory findings of 21 pa-
tients with HLH (10 benign disease-associated HLH and 11
LAHS). No significant differences were observed in the levels
of LDH or CRP levels. The mean sIL-2R levels (units per
milliliter) were significantly higher in the LAHS group (4,176
vs. 13,451, p=0.0031), and ferritin levels (nanogram per milli-
liter) were higher in the benign disease-associated HLH group
(20,462 vs. 2,561, p=0.0031). Consequently, the mean serum
sIL-2R/ferritin ratio of patients with LAHSwasmarkedly higher
than that of patients with benign disease-associated HLH (0.66
vs. 8.56, p=0.0004). Thus, the results of this study demonstrated
that the serum sIL-2R/ferritin ratio is a very useful marker for
diagnosing of LAHS, which was further supported by clinical
case analysis. Further studies to clarify the pathophysiology of
secondary HLH caused by various triggers are needed.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a clinico-
pathological entity characterized by the increased prolifer-
ation of benign macrophages that phagocytose blood cells
throughout the reticuloendothelial system [1]. HLH has
been classified into two distinct forms: primary or familial
HLH and secondary HLH. Secondary HLH is an etiolog-
ically heterogeneous entity that has been associated with
infections, autoimmune disorders, drugs, and malignant
disease, typically malignant lymphoma [2–4]. Lymphoma-
associated hemophagocytic syndrome (LAHS) is a subtype
that accounts for approximately 40 % of adult-onset sec-
ondary HLH and has a poor outcome [5]. Although the
early diagnosis of underlying conditions, especially malig-
nant lymphoma, leads to a better outcome, the diagnosis
of LAHS is often difficult because of the frequent lack of
mass formation and absence of distinct lymph node en-
largement, which results in the development of progressive
disease with an unfavorable prognosis. Tabata et al.
reviewed Japanese patients in the literature and proposed
that the serum soluble interleukin-2 receptor (sIL-2R)/fer-
ritin ratio could be a useful marker for predicting under-
lying malignant lymphoma in HLH patients [6]. Here, we
evaluated the serum sIL-2R/ferritin ratios of HLH patients
in our institution to confirm its utility in differentiating
LAHS from other reactive HLH.
Methods
Patients and methods
We retrospectively collected data on 21 patients who were
diagnosed with HLH (benign disease-associated HLH and
LAHS) between 2000 and 2011 at the Kumamoto City Hos-
pital. Data collected on each patient included age, presumed
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etiology, presence or absence of splenomegaly, white blood
cell (WBC), absolute neutrophil count (ANC), hemoglobin
(Hb), platelet (PLT), aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), lactate dehydrogenase (LDH),
triglycerides (TG), fibrinogen (Fib), C-reactive protein (CRP),
sIL-2R, ferritin, nuclear cell count (NCC), and percentage of
macrophages in the bone marrow. HLH was diagnosed ac-
cording to the HLH-2004 diagnostic guidelines [7]. Five of
the following eight criteria had to be fulfilled: (1) fever; (2)
splenomegaly; (3) cytopenia affecting at least two of three
lineages in the peripheral blood; (4) hypertriglyceridemia
(triglycerides of ≥265 mg/dl) and/or hypofibrinogenemia (fi-
brinogen of ≤150 mg/dl); (5) hemophagocytosis in the bone
marrow, spleen, or lymph nodes; (6) low or absent NK cell
activity; (7) hyperferritinemia (ferritin of ≥500 μg/l); and (8)
high levels of sIL-2R (≥2,400 U/ml). The diagnosis of malig-
nant lymphoma was made according to the 2008 WHO clas-
sification [8]. We compared the laboratory findings (WBC,
ANC, Hb, PLT, AST, ALT, LDH, CRP, ferritin, sIL-2R, and
sIL-2R/ferritin ratio) of the benign disease-associated HLH
group with those of the LAHS group. The nonparametric
Mann–Whitney U test was used to compare the values of




A total of 21 patients were included in this analysis. The clinical
characteristics of these patients are described in Tables 1, 2, 3,
and 4. Benign disease-associated HLH was diagnosed in 10
patients (case B1-10 in Tables 1 and 2; benign disease-
associated HLH group), and LAHS in 11 patients (case L1-11
in Tables 3 and 4; LAHS group).
The median age of the benign disease-associated HLH
group (Tables 1 and 2) was 43.6 years, ranging between 17
and 68 years. The etiologic subtypes were infection (pneumo-
nia, n =1; Epstein–Barr virus, n =1; cytomegalovirus, n =1;
and malaria, n =2), and autoimmune disorders (adult-onset
Still’s disease (AOSD), n =2). The underlying cause could
not be determined in two patients (cases B1 and B5) in spite of
tests being performed for the Epstein–Barr virus, cytomega-
lovirus, parvovirus, virus hepatitis (hepatitis A, B, and C),
sepsis, autoimmune disorders, drugs, and malignancy. Both
patients recovered with short-term immunosuppressive thera-
py (case B1, corticosteroid + cyclosporine; case B5, cortico-
steroid), and recurrences was not observed.
The median age of the LAHS group (Tables 3 and 4) was
72.0 years, ranging between 56 and 98 years. The most
frequent histopathological subtype was intravascular large
B cell lymphoma (IVLBCL), Asian variant (n =6), and
diffuse large B cell lymphoma (DLBCL), not otherwise
specified (NOS) (n =2), followed by peripheral T cell lym-
phoma (PTCL), NOS (n =2), and extranodal NK/T cell
lymphoma, nasal type (ENKL) (n =1). All patients in the
LAHS group were clinical stage IVB, and bone marrow
involvement was observed in nine patients. According to
the International Prognostic Index, all patients were cate-
gorized as high risk. Neither a distinct tumor mass nor
apparent lymph node enlargement was noted in six patients
(cases L1, L2, L4, L6, L7, and L8), and lymphoma was
diagnosed by bone marrow examination in four out of six
patients. One patient (case L2) was diagnosed with lym-
phoma by autopsy, and one patient (case L6) was diagnosed
with lymphoma by transbronchial lung biopsy (TBLB) and
random skin biopsy.
Table 1 Clinical characteristics of patients with benign disease-associated HLH




















B1 17 M Unknown 2,400 384 11.0 6.5 2,090 2,590 11.8 n.t. 198 0.5
B2 62 F Erythema exsudativum
multiforme
3,400 1,700 12.7 10.5 368 307 3.1 199 162 0.4
B3 52 M Pneumonia 2,400 1,176 13.5 4.2 427 328 4.2 n.t. 415 19.9
B4 31 M CMV 3,500 1,820 13.6 4.2 91 61 5.0 n.t. 478 23.6
B5 50 F Unknown 600 189 11.2 5.4 6,300 3,400 32.3 157 134 7.4
B6 50 M EBV 5,300 2,730 13.8 10.8 203 353 2.2 n.t. 333 3.1
B7 41 M Malaria 4,100 1,353 10.4 7.6 60 73 2.0 729 574 14.2
B8 33 M Malaria 2,600 1,300 10.7 4.3 40 74 1.4 310 456 19.8
B9 68 F AOSD 2,400 984 9.2 13.9 57 37 1.4 123 276 1.2
B10 32 F AOSD 13,800 12,765 11.6 4.3 1,978 1,820 17.5 239 188 3.8
ANC absolute neutrophil count, TG triglyceride, Fib fibrinogen, CMV cytomegalovirus, EBV Epstein–Barr virus, AOSD adult-onset Still’s disease,
UNL upper normal limit, n.t. not tested
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Laboratory findings
The laboratory findings of the initial presentation are summarized
in Tables 1 and 2 (case B1-10, the benign disease-associated
HLH group) and Tables 3 and 4 (case L1-11, the LAHS group).
All our patients fulfilled the required criteria for the diagnosis of
HLH. Although serum ferritin levels were under 1,000 ng/ml in
four cases (cases L6, L7, L11, and B6), hemophagocytosis by
activated macrophages was confirmed in the bone marrow.
One patient in the benign disease-associated HLH group
(10 %) had anemia (Hb≤10.0 g/dl), while seven patients
(70 %) had thrombocytopenia (PLT≤100,000/μl). Other
findings of interest were increased levels of LDH, ferritin,
CRP, and sIL-2R in all patients examined. One patient had
hypofibrinogenemia (fibrinogen of ≤150 mg/dl), and two pa-
tients had hypertriglyceridemia (triglycerides of ≥265 mg/dl).
Seven patients in the LAHS group (63.6 %) had anemia
(Hb≤10.0 g/dl), while six patients (54.5 %) had thrombocyto-
penia (PLT≤100,000/μl). LDH, CRP, ferritin, and sIL-2R
levels were elevated in all patients. Although very high CRP
was observed in two patients (cases L3 and L4), infection was
not complicated in both these patients. Two patients had
hypofibrinogenemia (fibrinogen of ≤150 mg/dl), and one pa-
tient had hypertriglyceridemia (triglycerides of ≥265 mg/dl).
Table 2 Clinical characteristics of patients with benign disease-associated HLH
Case Splenomegaly Hemophagocytosis
(bone marrow)
NCC (/μl) Histiocyte (%) HLH-2004 sIL2R (U/ml) Ferritin (ng/ml) sIL2R/ferritin
B1 + + 65.0×104 0.6 5 (8) 2,162 26,798 0.08
B2 + + 3.0×104 1.6 5 (8) 2,704 11,775 0.22
B3 + + 8.6×104 6.0 5 (8) 8,657 29,577 0.29
B4 + + 7.0×104 2.6 5 (8) 3,660 11,174 0.32
B5 + + 2.1×104 9.6 7 (8) 4,028 6,865 0.58
B6 + + 3.0×104 1.0 5 (8) 2,416 882 2.73
B7 + n.t. n.t. n.t. 5 (8) 2,563 6,947 0.37
B8 + n.t. n.t. n.t. 5 (8) 3,222 2,746 1.17
B9 + + 0.9×104 3.0 5 (8) 6,078 7,852 0.77
B10 + + 6.0×104 3.4 5 (8) 6,271 100,000 0.06
NCC nuclear cell count, n.t. not tested
Table 3 Clinical characteristics of patients with LAHS
























L1 73 M IVLBCL Bone marrow + IVB 4,100 3,342 10.8 7.6 25 19 1.7 213 n.t. 1.9
L2 67 M IVLBCL Autopsy + IVB 8,200 6,560 8.4 12.3 45 19 3.5 301 159 13.9
L3 98 F DLBCL,
NOS
Lymph node Not detected IVB 3,800 2,413 8.9 13.4 34 9 6.7 n.t. n.t. 29.3
L4 74 F IVLBCL Bone marrow + IVB 4,200 1,953 7.6 16.6 58 25 2.5 n.t. n.t. 17.3
L5 76 M DLBCL,
NOS
Lymph node + IVB 10,700 7,875 8.4 8.3 39 19 4.6 178 n.t. 9.0
L6 59 F IVLBCL Skin, lung Not detected IVB 4,900 2,793 9.0 20.5 46 8 8.9 408 306 8.2
L7 77 F IVLBCL Bone marrow + IVB 3,500 2,730 7.4 5.0 20 30 2.4 220 n.t. 3.0
L8 86 F IVLBCL Bone marrow + IVB 2,400 1,872 11.1 7.3 96 58 1.9 100 169 5.0
L9 56 M ENKL Liver + IVB 1,800 1,026 12.6 8.5 157 132 3.4 163 249 0.3
L10 62 F PTCL,
NOS
Lymph node + IVB 2,900 2,523 10.7 8.5 142 60 3.0 99 211 10.1
L11 65 F PTCL,
NOS
Skin + IVB 3,100 1,225 9.0 10.6 35 20 1.3 256 n.t. 1.1
ANC absolute neutrophil count; TG triglyceride; Fib fibrinogen; IVBCL intravascular B cell lymphoma; DLBCL, NOS diffuse large B cell lymphoma,
not otherwise specified; ENKL extranodal NK cell lymphoma; PTCL, NOS peripheral T cell lymphoma, not otherwise specified; UNL upper normal
limit; n.t. not tested
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Comparison of laboratory findings between LAHS
and benign disease-associated HLH
A comparison of laboratory findings between the LAHS and
disease-associated HLH groups is shown in Table 5. There were
no significant differences in LDH or CRP levels (p =0.53 and
p=0.94). Neutropenia and thrombocytopenia were more severe
in the benign disease-associated HLH group (p =0.045 and
p =0.045). Anemia was more severe in the LAHS group
(p =0.005). Liver enzymes in the benign disease-associated
HLH were higher than those in the LAHS group. The mean
sIL-2R levels were higher (p=0.0031), and the mean ferritin
levels were lower (p=0.0031) in the LAHS group than those in
thebenigndisease-associatedHLHgroup, respectively (Table 5).
Consequently, the mean serum sIL-2R/ferritin ratio of patients
with LAHS was markedly higher than that of patients with
benign disease-associated HLH (8.56 vs. 0.66, p =0.0004)
(Table 5).
Discussion
Secondary HLH presents in a number of different clinical
contexts with various etiologic associations. Patients typically
have concurrent infections/medical conditions that appear to
trigger their HLH, such as infection, malignancy, or autoim-
mune disorders [1–3]. In this study, we presented 21 second-
ary HLH cases diagnosed at a single institution. The major
etiology of our cases was lymphoma, followed by infection
(EBV, CMV, malaria), and AOSD. AOSD is a systemic in-
flammation disorder of unknown origin characterized by spik-
ing fever, rash, polyarthralgia, and hyperferritinemia.
Table 4 Clinical characteristics of patients with LAHS
Case Splenomegaly Hemophagocytosis NCC (/μl) Histiocyte (%) HLH-2004 sIL-2R (U/ml) Ferritin (ng/ml) sIL-2R/ferritin
L1 + + 11.0×104 1.0 5 (8) 9,221 2,613 3.52
L2 + + 6.4×104 2.4 5 (8) 9,793 3,273 2.99
L3 + + Dry tap 4.0 5 (8) 12,569 2,861 4.39
L4 + + 17.0×104 1.6 5 (8) 4,291 1,729 2.48
L5 + + 5.5×104 0.2 6 (8) 36,938 1,184 31.19
L6 + + 4.4×104 2.0 6 (8) 3,462 718 4.82
L7 + + 6.0×104 3.0 6 (8) 11,536 707 16.31
L8 + + 1.0×104 1.0 6 (8) 36,715 3,477 10.55
L9 + + 2.8×104 0.8 5 (8) 3,588 4,923 0.72
L10 + + 7.0×104 0.4 6 (8) 10,230 6,067 1.68
L11 + + 2.8×104 1.0 5 (8) 9,620 619 15.54
NCC nuclear cell count
Table 5 Comparison of the laboratory findings of the two groups (benign disease-associated HLH and LAHS)
Benign disease-associated HLH Range LAHS Range p value
Mean ± SD Mean ± SD
n =10 n =11
WBC (×109/l) 4,050±1,152 600–13,800 4,509±799 1,800–10,700 NS
ANC (×109/l) 2,440±1,170 189–12,765 3,119±650 1,026–7,875 <0.05
Hb (g/dl) 11.8±0.5 9.2–13.8 9.4±0.5 7.4–12.6 <0.01
PLT (×109/l) 7.2±1.1 4.2–13.9 10.8±1.4 5.0–20.5 <0.05
AST (U/l) 1,161±622 40–6,300 63.4±14.2 20–157 <0.01
ALT (U/l) 904±391 37–3,400 36.3±10.9 8–132 <0.001
LDH (/UNL) 8.1±3.2 1.4–32.3 3.6±0.7 1.3–8.9 NS
CRP (mg/dl) 9.4±2.9 0.4–23.6 9.0±2.6 0.3–29.3 NS
sIL-2R (U/ml) 4,176±677 2,162–8,657 13,451±3,611 3,462–36,938 <0.005
Ferritin (ng/ml) 20,462±9,330 882–100,000 2,561±544 619–6,067 <0.005
sIL-2R/ferritin 0.66±0.25 0.06–2.73 8.56±2.79 0.72–31.1 <0.0005
UNL upper normal limit, NS not significant
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Macrophage activation syndrome (MAS) is a life-threatening
complication of AOSD [9, 10]. Clinically, patients with MAS
present with high fever, pancytopenia, hepatosplenomegaly,
hepatic dysfunction, encephalopathy, coagulation abnormali-
ties, and sharply increased levels of ferritin. As MAS is
clinically similar to HLH, it is currently classified among the
secondary forms of HLH [8]. It is difficult to distinguish an
AOSD flare from HLH/MAS because HLH/MAS and AOSD
share several clinical features [11]. Preliminary diagnostic
guidelines have been presented for MAS, which consisted of
laboratory and clinical criteria [7]. There were two cases of
AOSD-associated HLH (cases B9 and B10) in this study, and
both of them satisfied the diagnostic criteria of MAS.
A Japanese survey revealed that LAHS was a major subtype
in adult-onset HLH cases and had a poor outcome [5]. LAHS
accounted for 43 % of HLH patients older than 15 years of age
and for 67 % of patients older than 60 years of age [5].
Approximately 46 % of patients with LAHS were associated
with B cell lymphoma (B-LAHS), and approximately 32 %
with NK/Tcell lymphoma (NK/T-LAHS) [5]. The predominant
histology of B cell tumors was DLBCL (15 %) and IVLBCL
(14 %), while PTCL (12 %) and ENKL (11 %) were the major
histologic subtypes noted among T/NK cell tumors [5]. Ishii
et al. analyzed the outcome of a distinct subtype of HLH and
showed that the 5-year overall survival rates were 48.2% for B-
LAHS, 12.2 % for NK/T-LAHS, 82.7 % for Epstein–Barr
virus-HLH, 89.0 % for other infection-associated HLH, and
89.6 % for autoimmune-associated HLH [5]. The lack of mass
formation and absence of apparent lymph node enlargement
often delays the diagnosis of LAHS, which results in the
progression of the disease and an unfavorable prognosis.
LAHS, especially IVLBCL with HLH, develops rapidly, and
a diagnostic delay contributes to fatal outcome. IVLBCL ac-
counts for 0.9 % of all lymphomas in Japan (Okamoto et al.
2009) and is characterized by fever and hepatosplenomegaly
without lymphadenopathy at initial presentation.
Tabata et al. reviewed 110 patients, including 57 LAHS
cases and 53 benign disease-associated HLH cases in the
literature, and demonstrated the important role of not only a
high serum sIL-2R level (≥5,000 U/ml) but also a high sIL-
2R/ferritin ratio (≥2.0) in the diagnosis of LAHS [6]. In
addition, they evaluated the positive predictive values of
parameters for LAHS. The positive predictive value (PPV)
for LAHS of high sIL-2R (≥5,000 U/ml) was 81.0 %, and the
PPV for LAHS of a high sIL-2R/ferritin ratio (≥2.0) was
85.2 % [6]. Moreover, the PPVof both parameters combined
was 95.6 % [6]. They then proposed that the serum sIL-2R/
ferritin ratio could be used as a useful marker to diagnosis of
LAHS. However, variations in the normal ranges of sIL-2R
and ferritin have been reported, depending on the various
assays used in different laboratories. In addition, neither the
clinical features of HLH patients nor the diagnostic criteria
were shown in this study.
Therefore, we attempted to analyze the laboratory findings
including parameters such as sIL-2R, ferritin, and sIL-2R/
ferritin in the HLH patients diagnosed in our institution to
verify this study. Our results showed that the level of sIL-2R
was significantly higher (p =0.0031) and the ferritin level was
lower (p =0.0031) in the LAHS group than that in the benign
disease-associated HLH group. Consequently, the mean se-
rum sIL-2R/ferritin ratio of patients with LAHS was signifi-
cantly higher than that of patients with benign disease-
associated HLH (p =0.0004) (Table 5). In the LAHS group,
a high serum sIL-2R level (≥5,000 U/ml) and high sIL-2R/
ferritin ratio (≥2.0) were observed in 8 and 9 out of 11 patients,
respectively. In contrast, cases with a high serum sIL-2R level
and high sIL-2R/ferritin ratio in the benign disease-associated
HLH group were only 2 and 1 out of 10 patients, respectively.
The clinical features of each case further revealed the
usefulness of these parameters. For example, the underlying
disease of HLH in case L2 (Tables 3 and 4) was not diagnosed
until IVBCL was confirmed by autopsy. The sIL-2R level and
sIL-2R/ferritin ratio at the diagnosis of HLHwere as high as 9,
793 U/ml and 2.99, respectively. In case L6 (Tables 3 and 4)
without lymphadenopathy or the bone marrow infiltration of
tumor cells, only TBLB and random skin biopsy confirmed
the presence of IVLBCL with HLH. Although the sIL-2R
level was relatively low (3,462 U/ml), the sIL-2R/ferritin ratio
was as high as 4.82. On the other hand, the underlying cause of
HLH in case B9 (Tables 1 and 2) was first suspected to be
malignant lymphoma because of elevations in LDH, sIL-2R,
and β2 microglobulin levels and abnormal uptakes by an
enlarged spleen on FDG-PET/CT scanning. Six months after
the diagnosis of HLH, the patient exhibited a typical rash and
arthralgia and was diagnosed with AOSD. At the diagnosis of
HLH, her sIL-2R level was less than 5,000 U/ml (4,733 U/ml),
and sIL-2R/ferritin ratio was as low as 0.45. Thus, both of these
parameters, especially the latter, appear to be useful for
predicting the presence of lymphoma in the background of
HLH.
The pathogenesis of secondary HLH is not as well under-
stood as that of primary HLH. However, secondary HLH is
also characterized by a marked elevation in the serum level of
sIL-2R and ferritin, both of which are the parameters of
diagnostic criteria [7]. Hyperferritinemia generally reflects
the activation of macrophages in HLH, while elevated levels
of sIL-2R reflect T cell activation [10–12]. Relatively high
sIL-2R and relatively low ferritin levels in LAHS result in a
markedly high sIL-2R/ferritin ratio, which ratio may indicate
excessive T cell activation related to the activation of macro-
phages in LAHS.
In summary, we evaluated the laboratory findings of HLH
patients in our institution and recognized the utility of the sIL-
2R/ferritin ratio for diagnosing LAHS. A high sIL-2R/ferritin
ratio strongly indicates the presence of underlying malignant
lymphoma.
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